Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 191,830 | 213,770 | 207,097 | 182,824 | 229,356 |
| Receivables | 700,251 | 708,856 | 734,482 | 767,569 | 756,629 |
| Inventories | 359,723 | 299,103 | 302,550 | 279,550 | 290,156 |
| Other current assets | 134,856 | 129,212 | 166,440 | 129,921 | 100,230 |
| TOTAL | $1,488,806 | $1,447,049 | $1,532,104 | $1,469,862 | $1,506,358 |
| Non-Current Assets | |||||
| PPE Net | 1,510,154 | 1,655,219 | 1,591,625 | 1,606,733 | 1,587,069 |
| Investments And Advances | 209,723 | 206,972 | 194,635 | 216,073 | 214,026 |
| Intangibles | 3,289,021 | 3,104,248 | 3,493,375 | 3,538,717 | 3,529,107 |
| Other Non-Current Assets | 1,232,604 | 721,934 | 702,073 | 729,160 | 745,806 |
| TOTAL | $6,241,502 | $5,688,373 | $5,981,708 | $6,090,683 | $6,076,008 |
| Total Assets | $7,730,308 | $7,135,422 | $7,513,812 | $7,560,545 | $7,582,366 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 133,952 | 148,800 | 169,615 | 145,798 | 149,334 |
| Accrued Expenses | 539,285 | 538,939 | 498,592 | 459,076 | 439,792 |
| Other current liabilities | 226,137 | 222,158 | 215,953 | 207,224 | 211,467 |
| TOTAL | $1,093,704 | $1,120,315 | $1,121,888 | $1,080,438 | $1,051,055 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,663,133 | 2,136,360 | 2,185,453 | 2,332,374 | 2,510,754 |
| Deferred Revenues | 194,330 | 210,418 | 237,728 | 268,340 | 250,462 |
| Other Non-Current Liabilities | 945,618 | 613,348 | 672,005 | 678,463 | 712,761 |
| TOTAL | $3,690,191 | $2,845,176 | $2,981,599 | $3,120,477 | $3,331,192 |
| Total Liabilities | $4,783,895 | $3,965,491 | $4,103,487 | $4,200,915 | $4,382,247 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 48,168 | 49,228 | 49,215 | 49,214 | 49,116 |
| Common Shares | 493 | 492 | 514 | 513 | 512 |
| Retained earnings | 1,373,777 | 1,388,620 | 1,944,317 | 1,889,895 | 1,837,569 |
| Other shareholders' equity | -185,213 | -166,482 | -187,171 | -160,496 | -259,014 |
| TOTAL | $2,946,413 | $3,169,931 | $3,410,325 | $3,359,630 | $3,200,119 |
| Total Liabilities And Equity | $7,730,308 | $7,135,422 | $7,513,812 | $7,560,545 | $7,582,366 |